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Daniel S StrausAbstract
Background: Inflammation is a well-known etiological factor for colorectal cancer, but mechanisms underlying the
linkage between inflammation and cancer are incompletely understood. We hypothesized that two pro-inflammatory
cytokines, TNFα and IL-17, might play a role in promoting colorectal carcinogenesis. Aerobic glycolysis is a metabolic
adaptation that promotes the survival/proliferation of cancer cells. Paracrine signaling between tumor cells and cancer-
associated fibroblasts also plays a role in carcinogenesis.
Methods: The effect of TNFα and IL-17 on aerobic glycolysis and growth factor production in cultured human
colorectal cancer cells was investigated. Glucose utilization and lactate production were quantified by measuring the
disappearance of glucose and appearance of lactate in the culture medium. Glucose transporter and glycolytic enzyme
expression levels were measured by immunoblotting.
Results: TNFα and IL-17 cooperatively stimulated glycolysis in HT-29, T84, Caco-2 and HCT116 colorectal cancer cells.
Treatment of HT-29 cells with TNFα plus IL-17 also increased the expression of HIF-1α and c-myc, two factors know to
induce the transcription of genes encoding components of the glycolytic pathway. To further investigate mechanisms
for cytokine-stimulated glycolysis, the effects of TNFα and IL-17 on expression of six members and one regulator of the
glycolytic pathway were investigated. TNFα and IL-17 cooperatively increased the expression of the glucose transporter
SLC2A1 and hexokinase-2 but did not regulate expression of glucose transporter SLC2A3, enolase-1, pyruvate kinase
M2, lactate dehydrogenase A, or 6-phoshofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3). Experiments with
inhibitors indicated that HIF-1α played a role in induction of SLC2A1 and that the transcription factor NF-κB played a
role in induction of hexokinase-2 by TNFα and IL-17. TNFα and IL-17 also synergistically stimulated production by HT-29
cells of a growth factor that simulated proliferation/survival of NIL8 fibroblastic cells. The activity of this factor was not
specifically inhibited by the EGFR inhibitor AG1478, indicating that it is not an EGFR ligand.
Conclusions: Chronic inflammation is known to promote colorectal tumorigenesis. The pro-inflammatory cytokines
TNFα and IL-17 may contribute to this effect by stimulating glycolysis and growth factor production in colorectal
cancer cells.
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Considerable evidence has accumulated recently impli-
cating inflammation as a causative factor in tumorigen-
esis [1,2]. There were an estimated 142,570 new cases of
colorectal cancer (CRC) in the US in 2010, and CRC is
the second most common cause of cancer death in the
US [3]. A role for inflammation in causation of CRC is
well documented [4,5]. For example, patients with in-
flammatory bowel disease (ulcerative colitis and Crohn’s
disease) have a greatly increased risk for colorectal can-
cer [4,5]. Moreover, non-steroidal anti-inflammatory
drugs such as aspirin and cyclooxygenase inhibitors have
been shown to decrease the occurrence of adenomatous
polyps [6]. However, despite clear evidence implicating
inflammation in causation of CRC and other cancers,
molecular mechanisms underlying this phenomenon are
incompletely understood.
Much interest has focused recently on metabolic ab-
normalities in cancer cells. Among these, aerobic gly-
colysis (i.e. the Warburg effect) is a metabolic adaptation
that promotes the survival/proliferation of cancer cells
[7-9]. Increased activity of the glycolytic pathway pro-
vides biosynthetic substrates required by proliferating
cells, inhibits apoptosis, and results in increased produc-
tion of L-lactate, which exerts pro-carcinogenic effects
[7-10]. While increased expression/activity of transcrip-
tion factors HIF-1α and c-myc is thought to play an im-
portant role in the increased glycolysis in cancer cells,
the underlying mechanisms are not completely under-
stood [11-13]. HIF-1α is a master regulator of genes en-
coding components of the glycolytic pathway [11,12],
and c-myc also positively regulates some of these same
genes [13-15]. High activity of the PI3 kinase-AKT sig-
naling pathway in cancer cells appears to be causally re-
lated to the increased expression of HIF-1α and c-myc
[13]. Growth factors such as EGF and insulin increase
the expression of HIF-1α [16,17], and a few studies have
implicated cytokines as regulators of HIF-1α [18-20].
The two cytokines, TNFα and interleukin 17 (IL-17,
also called IL-17A), play an important role in both acute
and chronic inflammation. The importance of TNFα in
inflammatory bowel disease is illustrated by the efficacy
of anti-TNFα monoclonal antibodies in treating Crohn’s
disease and ulcerative colitis [21]. In the gut, IL-17 is
produced by a number of innate immune cells including
innate lymphoid cells (ILC) [22,23]. In the adaptive im-
mune response, IL-17 is produced by Th17 cells [24].
IL-17 expression is increased in inflammatory bowel dis-
ease [25], and tumor-infiltrating Th17 cells are found in
human colorectal cancer and are associated with short-
ened disease-free survival [26,27]. Recent studies with
mouse models have also revealed a role for IL-17 signal-
ing in the development of colorectal tumors [28]. TNFα
is produced in colorectal tumors by infiltratingmacrophages, and higher TNFα expression is correlated
with increased tumor diameter [29]. Thus, TNFα and
IL-17 are frequently both present in acute and chronic
inflammation, and both have been linked to colorectal
cancer. The combined effect of the two cytokines on
tumor cell metabolism and growth is therefore of con-
siderable interest.
Previous studies of the regulation of gene expression
by TNFα plus IL-17 have shown cooperative effects, in
which TNFα induces transcription of target genes while
IL-17 stabilizes their mRNAs [30,31]. The transcription
factor NF-κB is an important mediator of transcriptional
effects of TNFα in target cells including colorectal can-
cer cells [30]. Moreover, IL-17 synergizes with TNFα to
induce expression of a number of genes including those
encoding chemokines such as CXCL1, CXCL8, and
CCL20 [30]. Major mechanisms for this effect are activa-
tion of the canonical NF-κB signaling pathway by TNFα
resulting in increased gene transcription, and IL-17-
mediated stabilization of mRNAs [30,31].
Heterotypic interactions between tumor cells and stro-
mal cells in the surrounding microenvironment play an
essential role in tumorigenesis [32]. Stromal cancer-
associated fibroblasts (CAF) and tumor cells form a re-
ciprocal positive feedback loop, in which the tumor cells
produce factors that promote activation, proliferation
and chemotaxis of CAF, which in turn produce factors
that enhance tumor cell proliferation [33-35]. Inhibition of
CAF signaling pathways thus inhibits tumorigenesis [36].
In the present study we examined the effect of TNFα
and IL-17 on glycolysis and growth factor production in
colorectal cancer cells. The results indicate that the two
cytokines cooperate to increase activity of the glycolytic
pathway and to increase production of growth factor(s)
that enhance the proliferation/survival of fibroblastic
cells.
Results
The effect of TNFα, IL-17, and TNFα plus IL-17 on glu-
cose utilization in HT-29 human colorectal cancer cells
is shown in Figure 1A. Treatment with TNFα modestly
stimulated glucose utilization by the HT-29 cells. Treat-
ment with IL-17 alone had no effect, but IL-17
synergized with TNFα to strongly stimulate glucose
utilization. TNFα and IL-17 also cooperatively stimu-
lated glucose utilization by three other human colorectal
cancer cell lines, HCT116, T84 and Caco-2 (Figure 1B,C,D).
As observed with the HT-29 cells, the effect of TNFα plus
IL-17 was synergistic in T84 and Caco-2 cells whereas in
HCT116 cells the effect of TNFα plus IL-17 was roughly
additive. The effect of TNFα and IL-17 on production of
L-lactate by HT-29 cells is shown in Figure 1E. TNFα and
IL-17 synergistically stimulated lactate production, indicat-
ing that the increased glucose utilization elicited by TNFα
Figure 1 Effect of TNFα (25 ng/ml) and IL-17 (50 ng/ml) on glucose utilization and lactate production of human colorectal cancer cell lines.
Colorectal cancer cell lines (A, HT-29; B, HCT116; C, T84, and D, Caco-2) were treated for 24 h with cytokines as shown. The medium was harvested and
assayed for D-glucose. Glucose utilization was expressed as percentage decrease of glucose in the medium. E. Production of L-lactate by HT-29 cells.
Cells were treated with cytokines as shown. The medium was harvested and assayed for L-lactate. F. Effect of EGFR-selective tyrosine protein kinase
inhibitor AG1478 on cytokine-stimulated glucose utilization by HT-29 cells. Cells were treated for 24 h with cytokines as shown, with or without
AG1478 (1 μM). Culture medium samples were then assayed for D-glucose as in panels A-D. G. Effect of TNFα plus IL-17 on HT-29 cell numbers.
Cultures were treated with vehicle or cytokines for 24 h, and cells were then harvested and counted. In panels A-F, each bar represents the mean ± SE
of three replicate cultures; in panel G each bar represents the mean ± SE of six replicate cultures. Means with different letters were significantly
different, P < 0.05. In panel G, n.s. = not significant based on t-test.
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end product of the glycolytic pathway, L-lactate.
Treatment of HT-29 cells with TNFα transactivates
the EGF receptor (EGFR), and this effect is augmented
by IL-17 [30,37]. Therefore, it was possible that the ef-
fect of the two cytokines on glucose metabolism might
be mediated by EGFR signaling. In support of this no-
tion, EGF has been shown to simulate glucose metabol-
ism in other cells [38,39]. The EGFR-selective receptor
tyrosine kinase inhibitor AG1478 (1 μM), which com-
pletely inhibits EGFR signaling at this high concentration
[40], only modestly inhibited the stimulation of glucose
metabolism by TNFα plus IL-17 (Figure 1F). Thus signal-
ing via pathway(s) other than the EGFR pathway appears
to be involved in the regulation of glucose metabolism.
Treatment of HT-29 cells for 24 h with TNFα plus IL-17
did not significantly affect cell numbers (Figure 1G).
Stimulation of glycolysis in cancer cells under hypoxic
conditions is thought to be mediated largely by activa-
tion of the transcription factor HIF-1α, a master regula-
tor of genes encoding a number of components of the
glycolytic pathway [11,12]. The transcription factor c-myc
also positively regulates several of these genes [13-15]. The
effect of a 4 h treatment with TNFα, IL-17, or TNFα +
IL-17 on expression of HIF-1α and c-myc protein is
shown in Figure 2. IL-17 synergized with TNFα to in-
crease expression of HIF-1α and also cooperated with
TNFα to increase the expression of c-myc (Figure 2).
The PI3K-AKT signaling pathway has been reported to
play a major role in mediating the regulation of HIF-1α
expression in cancer [13] and in response to growth fac-
tors [16,17]. We therefore considered the possibility that
PI3K-AKT signaling might mediate the effect of TNFα +
IL-17 on HIF-1α expression. TNFα + IL-17 dramatically
increased the phosphorylation of AKT in HT-29 cells,
with a maximal effect observed at 15 min (Figure 3A).
This effect was entirely blocked by the PI3K inhibitorFigure 2 Effect of TNFα and IL-17 on HIF-1α and c-myc expression in
for 4 h with TNFα (25 ng/ml) and/or IL-17 (50 ng/ml), or vehicle (control cu
lane) were run in 7.5% gels. (A). Western blots were prepared and probed
analysis. Each bar represents the mean of results obtained for duplicate culLY294002 and substantially inhibited by the EGFR in-
hibitor AG1478 (Figure 3B), but was unaffected by the
Src inhibitor SU6656 Figure 3C. This result suggested
that transactivation of EGFR contributed to PI3K path-
way activation in response to TNFα + IL-17, but that Src
pathway signaling, which sometimes mediates EGFR
transactivation [41], was not involved. TNFα strongly in-
creased AKT phosphorylation (Figure 3D,E). In contrast,
IL-17 had a very modest effect that did not attain statis-
tical significance, and it also did not significantly augment
TNFα-stimulated AKT phosphorylation (Figure 3D,E).
Therefore, activation of the PI3K signaling pathway might
contribute to TNFα-mediated stimulation of HIF-1α ex-
pression, but it did not account for the cooperative effect
of IL-17 in combination with TNFα shown in Figure 2.
The results shown in Figure 2 suggested that the effect
of TNFα and IL-17 on glycolysis might be mediated by
increased expression/activation of HIF-1α and c-myc,
leading to transcriptional induction of genes encoding
components of the glycolytic pathway. To test this idea,
we examined the effect of TNFα and IL-17 on expres-
sion of six components of the pathway: the glucose
transporters SLC2A1 (Glut1) and SLC2A3 (Glut3),
hexokinase-2 (HK2), enolase-1 (ENO1), pyruvate kinase
M2 (PKM2), and lactate dehydrogenase A (LDHA).
These correspond to the first two steps of the glycolytic
pathway (glucose transport and HK2), and the last three
steps (ENO1, PKM2, and LDHA). We also examined the
effect of TNFα on expression of 6-phoshofructo-2-kinase/
fructose-2,6-bisphosphatase-3 (PFKFB3), which produces
fructose-2,6-bisphosphate, a major allosteric regulator of
the glycolytic pathway enzyme 6-phosphofructo-1-kinase
[42]. The genes encoding all seven proteins are targets of
transcriptional activation by HIF-1α [12,42-44], and three
of them, (SLC2A1, HK2, and LDHA) are also well docu-
mented targets of c-myc [13-15]. The results (Figure 4A,B)
indicated that in cells treated for 12 h, TNFα and IL-17HT-29 cells. Duplicate serum-free cultures of HT-29 cells were treated
ltures), as indicated. Protein extract samples (60 μg of cellular protein/
for HIF-1α, c-myc, or α-tubulin. (B). Results were quantified by image
tures; the error brackets indicate the range for the duplicates.
Figure 3 Effect of TNFα and IL-17 on AKT phosphorylation on Ser473. Cultures of HT-29 cells were incubated in serum-free medium for 24 h
and then treated with vehicle, TNFα (25 ng/ml), IL-17 (50 ng/ml), or TNFα + IL-17. Western blots were prepared and probed with rabbit monoclonal
antibody specific for phospho-AKT (Ser473) or whole AKT. A. Time course for AKT phosphorylation. In subsequent experiments (B - E) cells were
treated for 15 min. B. Effect of EGFR inhibitor AG1478 (1 μM) or PI3K inhibitor LY294002 (20 μM) on AKT phosphorylation. C. Effect of Src inhibitor
SU6656 on AKT phosphorylation. D. Effect of vehicle, TNFα, IL-17, or TNFα + IL-17 on AKT phosphorylation. E. Effect of vehicle, TNFα, IL-17, or TNFα +
IL-17 on AKT phosphorylation, quantified by image analysis. Each bar represents the mean ± SE of four replicate cultures. Means with different letters
were significantly different, P < 0.05.
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HK2, but did not regulate the expression of SLC2A3,
ENO1, PKM2, LDHA, or PFKFB3. In the case of SLC2A1,
IL-17 alone had no effect, but it gave a small but reprodu-
cible increase in the induction by TNFα. In the case of
HK2, IL17 and TNFα both increased expression, and the
two cytokines together had a greater effect than either
alone (Figure 4A,B). Very similar results were obtained
with cells treated for 24 h (Figure 4C).
Chetomin is a low molecular weight compound that
inhibits transcriptional activation by HIF-1α by blocking
its binding of the co-activator p300 [45]. The effect of
chetomin on cytokine-induced lactate production and
expression of SLC2A1 and HK2 is shown in Figure 5.
Chetomin partially inhibited the stimulation of lactate
production by TNFα + IL-17 in a dose-dependent man-
ner (Figure 5A). In another experiment performed inquadruplicate, 200 nM chetomin inhibited lactate pro-
duction by 24% in cells stimulated with TNFα + IL-17,
and a commensurate inhibition of glucose utilization
was also observed (Figure 5B). A partial inhibition by
chetomin of cytokine-stimulated SLC2A1 expression
was also observed (Figure 5C,D). The effective chetomin
dose range of 50-200 nM was very similar to that re-
quired for inhibition of HIF-1α action in other human
cancer cell lines [46]. In contrast chetomin had little or
no effect on HK2 expression (Figure 5C,D). Finally,
chetomin had no significant effect on cell numbers
under the conditions of our experiments (Figure 5E).
NF-κB plays a major role in mediating transcriptional
induction of genes encoding several chemokines in cells
treated with TNFα + IL-17 [30,31]. Several studies have
documented that TNFα activates NF-κB in HT-29 and
other human colorectal cancer cell lines [30,47,48]. The
Figure 4 Effect of TNFα and IL-17 on expression of glycolytic pathway components. Duplicate serum-free cultures of HT-29 cells were
treated for 12 h or 24 h with TNFα (25 ng/ml) and/or IL-17 (50 ng/ml), or vehicle (control cultures), as indicated. Protein extract samples (60 μg of
cellular protein/lane) were run in 7.5% gels. (A). Western blots were prepared with extracts of cells treated for 12 h and probed for SLC2A1, HK2,
SLC2A3, LDHA, PKM2, ENO1, PFKFB3, and α-tubulin. (B). Results for SLC2A1 and HK2 were quantified by image analysis. Each bar represents the
mean of results obtained for duplicate cultures; the error brackets indicate the range for the duplicates. (C). Western blots were prepared for HT-29 cells
treated for 24 h, and the results for SLC2A1 and HK2 were quantified by image analysis. Each bar represents the mean of results obtained for duplicate
cultures; the error brackets indicate the range for the duplicates.
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for NF-κB activation by TNFα [49]. To investigate the
possibility that NF-κB might participate in the induction
of SLC2A1 and/or HK2, the effect of the IKKβ-selective
inhibitor TPCA-1 [50] on cytokine-induced lactate pro-
duction and expression of SLC2A1 and HK2 was tested.The results indicated that TPCA-1 strongly inhibited the
cytokine-stimulated component of lactate production by
HT-29 cells (Figure 6A). A similar strong inhibition of
cytokine-stimulated HK2 expression was also observed
(Figure 6B,C). In contrast TPCA-1 had little or no effect
on SLC2A1 expression (Figure 6B,C). The combined
Figure 5 Inhibition by chetomin of cytokine-stimulated lactate production, glucose utilization, and expression of SLC2A1 and HK2 by
HT-29 cells. Serum-free cultures of HT-29 cells were pre-treated with chetomin or vehicle for 4 h, and TNFα (25 ng/ml) + IL-17 (50 ng/ml) was then
added to some of the cultures for an additional 12 h. Medium samples were then collected for lactate and glucose assays, and protein extract samples
of cell monolayers (30 μg of cellular protein/lane) were run in 7.5% gels. (A). Effect of increasing concentrations of chetomin on lactate production.
Analysis of the data by linear regression showed a significant dose-dependent inhibition of lactate production by chetomin, P = 0.01. (B). Inhibition of
lactate production (top) and glucose utilization (bottom) by 200 nM chetomin. Solid black and cross-hatched bars represent the means ± SE of assays
performed with medium samples from quadruplicate cultures. Chetomin significantly inhibited lactate production and glucose utilization in cells
stimulated by TNFα+ IL-17, P < 0.001. (C). Western blots of cell extract proteins were probed for SLC2A1, HK2, or α-tubulin. (D). Results of Western blots
shown in panel C were quantified by image analysis. Analysis of the data by linear regression showed significant dose-dependent inhibition by
chetomin of SLC2A1 (P = 0.005) but not HK2 (P = 0.67, n.s.) expression. (E). Effect of chetomin on HT-29 cell numbers. Cultures were treated with vehicle
or chetomin for 16 h, and cells were then harvested and counted. Each bar represents the mean ± SD of results obtained with six cultures. Bars with
different letters were significantly different, P < 0.05.
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plays a role in the induction of SLC2A1 by TNFα + IL-17,
and that NF-κB plays a role in the induction of HK2.
Paracrine signaling between tumor cells and tumor-
associated stromal cells plays an important role in car-
cinogenesis. We next used the NIL8 fibroblastic cell lineto determine whether TNFα and IL-17 regulated pro-
duction of growth factors that are active in fibroblastic
cells. The NIL8 cells have been shown previously to re-
spond to a variety of growth factors that stimulate the
proliferation of fibroblasts [51-53]. The results (Figure 7A)
demonstrated that TNFα stimulated growth factor release
Figure 6 Inhibition by TPCA-1 of cytokine-stimulated lactate production and expression of SLC2A1 and HK2 by HT-29 cells. Serum-free
cultures of HT-29 cells were treated for 12 h with TNFα (25 ng/ml) + IL-17 (50 ng/ml), in the presence of TPCA-1 or vehicle, as shown. Medium
samples were then collected for lactate assays, and protein extract samples of cell monolayers (30 μg of cellular protein/lane) were run in 7.5%
gels. (A). Effect of increasing concentrations of TPCA-1 on lactate production. Analysis of the data by linear regression showed a significant dose-
dependent inhibition of lactate production by TPCA-1, P = 0.006. (B). Western blots of cell extract proteins were probed for SLC2A1, HK2, or α-tubulin.
(C). Results of Western blots shown in panel B were quantified by image analysis. Analysis of the data by linear regression showed significant dose-
dependent inhibition by TPCA-1 of HK-2 (P = 0.005) but not SLC2A1 (P = 0.84, n.s.) expression.
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the effect of TNFα on growth factor production. Insulin
was used as a positive control in the NIL8 bioassay
(Figure 7A). TNFα and IL-17 at the maximum possible
concentration remaining in the conditioned medium
had no significant effect on growth/survival of the NIL8
cells, showing that the growth factor activity was not at-
tributable to residual TNFα plus IL-17 (Figure 7B).
As noted above, TNFα transactivates the EGF receptor
(EGFR) in HT-29 cells, and this effect is augmented by
IL-17 [30,37]. The TNFα-elicited component of this ef-
fect is reported to involve release of the EGFR ligand
transforming growth factor-α (TGF-α) and its subse-
quent activation of EGFR [37]. Thus, it was possible that
the growth factor activity detected in the NIL8 bioassay
corresponded to EGFR ligand(s) released by the HT-29
cells in response to TNFα plus IL-17. To determine
whether this was the case, we examined the effect of the
selective EGFR tyrosine kinase inhibitor AG1478 on ac-
tivity of the HT-29-derived growth factor in NIL8 cells
(Figure 7C). As controls we used EGF, which acts en-
tirely via EGFR, and insulin, which at high concentra-
tions acts via the insulin receptor (IR) and IGF receptor-
1 (IGFR1) [54]. As expected, AG1478 strongly inhibited
EGF action in the NIL8 cells, with 50% inhibitionobserved at 100 nM AG1478 (Figure 7C). In contrast,
AG1478 at higher concentrations weakly inhibited insu-
lin signaling, presumably due to non-specific inhibition of
IR and IGFR1 tyrosine kinase activity. The AG1478 inhib-
ition curve for the activity produced by HT-29 cells was
identical to that of insulin, indicating that this growth fac-
tor does not act primarily through EGFR (Figure 7C).
Discussion
Chronic inflammation is a well-known risk factor for
colorectal cancer, but molecular mechanisms underlying
the effects of inflammation on carcinogenesis are incom-
pletely understood. Procarcinogenic effects of cytokines
produced by inflammatory cells are thus of considerable
interest. TNFα and IL-17 are commonly found together in
the context of both acute and chronic inflammation;
therefore, the effects of TNFα + IL-17 are biologically rele-
vant to the inflammation-cancer interface. The present re-
sults show that TNFα and IL-17 synergistically stimulate
glycolysis and growth factor production by human colo-
rectal cancer cells, effects that could contribute to the
positive effect of inflammation on carcinogenesis.
The transcription factor HIF-1α is a master regulator
of genes encoding components of the glycolytic pathway,
and c-myc also positively regulates some of these genes.
Figure 7 Medium conditioned by HT-29 cells treated with TNFα and IL-17 stimulates growth/survival of NIL8 cells. (A). NIL8 cells were treated
for 24 h with nothing, or 10 μl unconditioned medium (open bars), or insulin (1 μg/ml) (filled gray bar), or 10 μl of medium conditioned by cultures of
HT-29 cells treated with vehicle (control), TNFα, IL-17, or TNFα + IL-17 (filled black bars). Cell growth/survival of the NIL8 cells was then assayed
(Methods). Each bar is the mean of quadruplicate assays ± SE. Means with different letters were significantly different, P < 0.05. (B). Cell growth/survival
of NIL8 cells treated with: Bar 1: unconditioned McCoys 5A medium; Bar 2: medium conditioned by HT-29 cells stimulated with 25 ng/ml TNFα +
50 ng/ml IL-17 for 24 h; Bar 3: unconditioned medium containing 25 ng/ml TNFα + 50 ng/ml IL-17. Means with different letters were significantly
different, P < 0.05. (C). NIL8 cells were treated for 24 h with EGF (300 ng/ml) (○), insulin (10 μg/ml) (■), or 10 μl of medium conditioned by HT-29 cells
stimulated with TNFα + IL-17 (▲), plus increasing concentrations of AG1478. Cell growth/survival vs. unstimulated control NIL8 cells was then assayed
(Methods). Data were plotted as % growth stimulation observed in the absence of AG1478. Results show the means of quadruplicate assays ± SE.
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HIF-1α and c-myc in HT-29 cells. Of particular interest,
the effect of TNFα and IL-17 on HIF-1α was synergistic
and therefore resembled the synergistic effect of the two
cytokines on glycolysis in HT-29, T84 and Caco-2 cells(Figure 1A,C,D,E). We initially hypothesized, therefore,
that HIF-1α produced in response to TNFα plus IL-17
might globally induce transcription of genes encoding
components of the glycolytic pathway, and that c-myc
might also contribute to this induction. To test this idea
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nents and one regulator of the glycolytic pathway were ex-
amined. The genes encoding all seven proteins are known
targets of HIF-1α [12,41-43], and three of them (SLC2A1,
HK2 and LDHA) are also well-documented targets of
c-myc [13-15]. Surprisingly, TNFα and IL-17 selectively
induced expression of SLC2A1 and HK2 but did not
regulate the expression of SLC2A3, ENO1, PKM2,
LDHA, or PFKFB3. The glucose transporter SLC2A1
(also known as Glut1) facilitates the uptake of glucose,
and HK2 catalyzes the first step in glycolysis, phosphor-
ylation of D-glucose to yield D-glucose-6-phosphate.
HIF-1α was initially identified as a mediator of effects
of hypoxia, and these effects vary in a cell type-specific
manner. Relevant to the present results, selective induc-
tion of HK2 and pyruvate dehydrogenase kinase-1 (PDK1)
by hypoxia (and HIF-1α and c-myc) was observed in a
previous study of human P493-6 B-lymphoblastoid cells, a
model for human Burkitt’s lymphoma [55]. In these cells,
several other putative HIF-1α/c-myc targets including
ENO1 and LDHA were not regulated by hypoxia, HIF-1α
or c-myc [55]. Similarly, in MCF7 breast cancer cells
SLC2A1, HK2, and PFKFB3 but not ENO1 or LDHA were
strongly induced by hypoxia [56]. In contrast, hypoxia and
HIF-1α induced expression of ENO1 and LDHA in an-
other human cancer cell line, HEP3B hepatoma cells
[57,58]. The difference in response of various HIF-1α tar-
get genes to changes in HIF-1α observed in different can-
cer cell lines remains to be investigated further. Possible
explanations include higher or lower affinities of different
binding sites for HIF-1α, sequence context or chromatin
configuration of the binding sites, different basal levels of
expression of HIF-1α target genes in different cancer cells,
or differences in experimental protocols from study to
study.
The PI3K-AKT signaling pathway plays an important
role in regulating HIF-1α expression in cancer [13] and
in response to growth factors [16,17]. In the present
study AKT was activated in response to TNFα but not
IL-17. This activation of AKT was largely mediated by
EGFR transactivation, as it was strongly inhibited by the
selective EGFR tyrosine kinase inhibitor AG1478. How-
ever, AG1478 had a minimal effect on stimulation of gly-
colysis by TNFα + IL-17 (Figure 1F), that resembled the
~25% non-specific inhibition by 1 μM AG1478 of recep-
tor tyrosine kinases other than EGFR (Figure 7C). This
indicates that signaling events other than EGFR transac-
tivation play an important role in induction of glycolysis
by TNFα + IL-17.
Chetomin is a low molecular weight compound pro-
duced by the mold Chaetomium cochliodes that inhibits
transcriptional activation by HIF-1α [45]. Chetomin elic-
ited a dose-dependent partial inhibition of TNFα plus
IL-17-stimulated lactate production, which correlatedwith inhibition of SLC2A1 but not HK2 induction. The
effective chetomin dose range and degree of inhibition
of cytokine-stimulated SLC2A1 expression was remark-
ably similar to that seen for inhibition by chetomin of
hypoxia-stimulated expression of two other HIF-1α tar-
gets, CA9 and VEGF, in HT1080 human fibrosarcoma
cells [46]. The results presented here therefore suggest that
HIF-1α-mediated induction of SLC2A1 plays a role in the
stimulation of glycolysis by TNFα + IL-17. The SLC2A1
gene has been shown previously to be a HIF-1α target ,
and ChIP-Seq and ChIP-Chip analysis has identified a
HIF-1α binding site upstream of the SLC2A1 gene [59-61].
IL-17 synergizes with TNFα to induce expression of
chemokines such as CXCL1, CXCL8, and CCL20 in HT-
29 and other cells [30]. Major mechanisms for this in-
duction are activation of the canonical NF-κB signaling
pathway by TNFα, resulting in increased chemokine
gene transcription, and IL-17-mediated stabilization of
chemokine mRNAs [31,32]. The possibility was therefore
considered that NF-κB might play a role in the induction
of glycolysis by TNFα + IL-17. The protein kinase IKKβ
is a key component of the canonical NF-κB signaling
pathway, and TPCA-1 is a selective inhibitor of IKKβ
[50]. Interestingly, TPCA-1 strongly inhibited TNFα plus
IL-17-stimulated lactate production and induction of
HK2 but not SLC2A1. These results suggest that NF-κB
-mediated induction of HK2 plays a role in the stimula-
tion of glycolysis by TNFα + IL-17. The ENCODE pro-
ject has accomplished human genome-wide mapping of
binding sites for NF-κB and a number of other tran-
scription factors [62]. The results of the ENCODE pro-
ject are now displayed in the human genome database
(http://genome.ucsc.edu). Within intron 1 of the HK2
gene, there is a sequence that is bound by NF-κB in four
human lymphoblastoid cell lines and that maps to a
DNase-1 hypersensitive site. In the current assembly
(hg19) of the human genome sequence, the coordinates
for this sequence are chr 2: 75076257-75076681. This
interval contains a sequence on the opposite strand 5′-
GGGGCATTCC-3′, which agrees with the consensus
NF-κB binding sequence GGGRNNYYCC [63]. It is pos-
sible that this site might play a role in induction of HK2
expression by TNFα + IL-17.
Evidence indicates that cancer-associated fibroblasts
(CAF) and tumor cells form a reciprocal positive feedback
loop in which tumor cells produce factors that promote
activation, proliferation, and chemotaxis of CAF, which in
turn produce factors that enhance tumor cell proliferation
[33-36]. The results presented here demonstrate that IL-
17 synergizes with TNFα to stimulate the production by
HT-29 cells of a factor that increases proliferation/survival
of fibroblastic cells. Similar to the effect of TNFα and IL-
17 on glycolysis, IL-17 alone did not affect production of
the factor but it significantly enhanced TNFα-stimulated
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primarily via EGFR, and its identity remains to be
investigated.
Human colorectal tumors contain CD11c+ macrophage-
like cells that produce TNFα [29], and Th17 cells that pro-
duce IL-17 [26,27]; thus, the two cytokines are both
expressed in colorectal tumors. Moreover, increased TNFα
expression is correlated with increased diameter and ex-
tent of primary tumors [29], and studies of mouse models
have indicated that IL-23/IL-17 signaling plays a key role
in colorectal tumor development [28]. In the present study
we investigated mechanisms for the apparent pro-
carcinogenic effect of TNFα and IL-17.
Conclusions
Based on the results presented here, stimulation of gly-
colysis and growth factor production are two mecha-




Human recombinant TNFα (210-TA) and IL-17A (317-IL)
were from R&D Systems. Anti-PKM2 mouse monoclonal
antibody (5D2-3B3) and anti-SLC2A1 and SLC2A3 poly-
clonal antibodies used for Western blotting were from
Millipore. All other primary antibodies used for Western
blotting were from Cell Signaling Technology. HRP-
conjugated secondary antibodies for Western blotting
were from Vector Laboratories. SuperSignal West Pico
Chemiluminescent Substrate, obtained from Thermo Sci-
entific, was used for detection of HRP-secondary anti-
bodies in Western blots. Chetomin, TPCA-1, and AG1478
were from Sigma-Aldrich. The glucose (HK) detection
reagent was from Sigma-Aldrich (#G3293). Rabbit
muscle lactate dehydrogenase (25 kU/mg) used for
assaying L-lactate was from EMD Millipore.
Cell culture
Human colorectal cancer (CRC) cell lines HT-29, T84,
HCT119, and Caco-2 were cultured at 37 C in McCoy’s
5A medium supplemented with 15 mM HEPES, 10%
FBS, penicillin (100 U/ml) and streptomycin (100 μg/ml).
The NIL8 hamster fibroblastic cell line [51-53] was
cultured in MEM supplemented with 10% FBS, non-
essential amino acids, penicillin (100 U/ml) and strep-
tomycin (100 μg/ml). Cell counts were performed
with a hemocytometer.
Glucose utilization, lactate production, and growth factor
experiments
CRC cells were plated at a density of 2 × 106 cells per
3.5 cm diameter well (6 well plates) in McCoy’s 5A
medium with 10% FBS and antibiotics. After 48 hours themedium was changed to serum-free McCoys 5A with anti-
biotics, and cells were cultured for an additional 24 h. At
this time the cells had grown to confluent monolayers.
The medium was aspirated, and the cultures were washed
once with PBS. Fresh serum-free McCoys 5A medium
plus antibiotics was then added to each well. TNFα
(25 ng/ml), IL-17 (50 ng/ml), or vehicle was then added as
indicated, and the cells were cultured for an additional
24 h. The medium was then harvested and stored at -80 C
prior to being assayed for glucose, L-lactate, or growth fac-
tor activity.
Glucose and L-lactate assays
For assaying the concentration of D-glucose in culture
media, the glucose (HK) assay reagent (Sigma-Aldrich
#G3293) was utilized. This method uses two enzymes,
hexokinase and glucose-6-phosphate dehydrogenase.
Hexokinase first catalyzes conversion of D-glucose to
glucose-6-phosphate. Glucose-6-phosphate dehydrogen-
ase then catalyzes the reaction of glucose-6-phosphate
and NAD+ to produce 6-phosphogluconate and NADH.
Progress of the reaction was monitored spectrophoto-
metrically by measuring production of NADH, which
absorbs light at 340 nm. The concentration of glucose
was determined using a standard curve. The concentra-
tion of D-glucose in McCoy’s 5A medium is 3 mg/ml.
Glucose utilized by the cells during the 24 h incubation
period was calculated as the difference between the
starting glucose concentration (i.e. in medium not incu-
bated with cells) and the final glucose concentration in
medium incubated with cells, and was expressed as a
percentage of the starting concentration.
The production of L-lactate by cultured cells was
assayed enzymatically with rabbit muscle lactate de-
hydrogenase (EMD Millipore Corp, 25 kU/mg), as de-
scribed in ref. [64]. The starting medium, serum-free
McCoy’s 5A, does not contain L-lactate. The concentra-
tion of L-lactate in medium after cell culture was deter-
mined using a standard curve.
Growth factor assays
Bioassays of growth factor activity in cell culture media
were performed using the NIL8 hamster fibroblastic cell
line, which responds to a variety of growth factors that are
active in fibroblasts [51-53]. The Lonza ViaLight Plus cell
proliferation kit was used for these assays. The kit mea-
sures the amount of ATP in monolayer cultures and there-
fore measures cell proliferation/survival. Briefly, NIL8 cells
were plated in 96 well cell culture plates in MEM plus
0.3% serum, non-essential amino acids and antibiotics.
After 24 h, additions of cell culture medium samples were
made as indicated. The cells were then incubated for 24 h,
lysed, and the amount of ATP per well was determined
using the manufacturer’s protocol. Insulin, which
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as a positive control.
Protein expression experiments and AKT phosphorylation
assays
The effect of cytokines on expression of specific cellular
proteins and on AKT phosphorylation was determined
by Western blot analysis of whole cell extracts by stand-
ard methods as described previously [65]. Cells were
plated in 6 cm dishes at a density of 5-7 × 106 cells/dish,
and the cultures were incubated at 37 C until confluent.
The cultures were washed with PBS, fresh serum-free
medium was added, and the cultures were incubated for
24 h at 37 C. TNFα (25 ng/ml) and/or IL-17 (50 ng/ml),
or vehicle (control cultures), was then added, and incu-
bation was continued for the time indicated. The NETN
extraction buffer [65] used for preparing cell extracts
was supplemented with a protease inhibitor mix
obtained from Sigma-Aldrich (#P8340) and phosphatase
inhibitors sodium fluoride, disodium β-glycerophosphate
, sodium pyrophosphate, and sodium vanadate. In all ex-
periments the concentration of protein in each cell ex-
tract was determined by the method of Lowry [66], and
30 or 60 μg of extract protein was loaded in each lane of
the gel. For Western blot analysis of SLC2A1 expression,
samples were not boiled prior to loading the gels, to pre-
vent aggregation of SLC2A1 protein [67]. For measure-
ments of AKT phosphorylation, Western blots were
probed with monoclonal antibodies that specifically
recognize phospho-AKT (Ser473) or total AKT (Cell Sig-
naling #4060S and #4691S). Methods for blotting the gels
and probing the blots were as described previously [65].
Statistics
The unpaired t-test was used for comparison of two
means. For comparison of more than two means, data
were subjected to one-way ANOVA followed by the
Student-Newman-Keuls multiple comparison test. Lin-
ear regression analysis was performed for evaluation of
inhibitor data, with P < 0.05 used as a cut-off for signifi-
cance of a downward trend in assay result plotted as a
function of increasing inhibitor concentration.
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